Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation
Texas Tech University Health Sciences Center, El Pason = 231 Sept 2015 to est. Jan 2027
Chronic Constipation · Diabete Mellitus
PepBank has 66 linaclotide studies with results. 65 of them gave linaclotide, with 389 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 389 results and 250 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Linaclotide is a 14-residue peptide with three disulfide bridges. It activates guanylate cyclase-C on the luminal surface of intestinal epithelial cells. Its labeled indications concern constipation disorders.
| Target | Action | Evidence |
|---|---|---|
| Guanylate cyclase CGUCY2CP25092 (opens in a new tab) | Agonist | Official prescribing information, mechanism of actionSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
14 amino acids · 3 disulfide bonds
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 3.85 · Net charge at pH 7.4: −1.06
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set, 3 disulfide. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 1.00 |
| 1 | 1.00 |
| 2 | 0.97 |
| 3 | 0.73 |
| 4 | −0.16 |
| 5 | −0.85 |
| 6 | −0.99 |
| 7 | −1.02 |
| 8 | −1.22 |
| 9 | −1.86 |
| 10 | −2.85 |
| 11 | −3.77 |
| 12 | −3.97 |
| 13 | −4.00 |
| 14 | −4.00 |
14 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 16158208(opens in a new tab)
C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)[C@@H](NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)OAn ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.
Eisenberg consensus (normalized) scale · + K, R · − D, E
Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.
| Position | Residue | Angle | Eisenberg consensus (normalized) |
|---|---|---|---|
| 1 | C | 0° | 0.29 |
| 2 | C | 100° | 0.29 |
| 3 | E | 200° | -0.74 |
| 4 | Y | 300° | 0.26 |
| 5 | C | 40° | 0.29 |
| 6 | C | 140° | 0.29 |
| 7 | N | 240° | -0.78 |
| 8 | P | 340° | 0.12 |
| 9 | A | 80° | 0.62 |
| 10 | C | 180° | 0.29 |
| 11 | T | 280° | -0.05 |
| 12 | G | 20° | 0.48 |
| 13 | C | 120° | 0.29 |
| 14 | Y | 220° | 0.26 |
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Linaclotide has 251 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
Studies by year
66 of 250 studies have results (26%), published 2007 to 2026. Top row: every study. Bottom row: studies with results about Linaclotide, by class. The rows use different scales.
Studies250 in all, 2007 to 2026
Studies with results66 in all, 2007 to 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
52 trials match. Highest phase first. Data from ClinicalTrials.gov.
25 of 52 trials
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT00730171Sept 2008 to Mar 2012
Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
NCT00765882Sept 2008 to Aug 2009
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
NCT0076599931 Oct 2008 to 31 Jan 2012
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT00938717Jul 2009 to Sept 2010
Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
NCT00948818Jul 2009 to Aug 2010
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
NCT01642914Aug 2012 to Aug 2013
Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
NCT02291679Oct 2014 to Aug 2015
25 trials · 2 ongoing · 1 not yet recruiting · 18 completed · 1 stopped early · 15 with posted results · source ClinicalTrials.gov (opens in a new tab)
Texas Tech University Health Sciences Center, El Pason = 231 Sept 2015 to est. Jan 2027
Chronic Constipation · Diabete Mellitus
Md Mehedi Shahriarn = 90est. 20 Feb 2026 to est. 31 Jan 2027
Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C) · Chronic Constipation · CIC · Constipation Predominant Irritable Bowel Syndrome
Universitaire Ziekenhuizen KU Leuvenn = 1010 Feb 2014 to 3 Jun 2015
Chronic Constipation
Haifeng Lann = 4441 Sept 2024 to est. 1 Oct 2025
Lactulose · Bowel Preparation
RenJi Hospitaln = 781 Jan 2021 to est. Feb 2022
Functional Dyspepsia · Constipation-predominant Irritable Bowel Syndrome
Ironwood Pharmaceuticals, Inc.n = 2021 Dec 2016 to 31 Oct 2018
Irritable Bowel Syndrome Characterized by Constipation
Forest Laboratoriesn = 8281 Nov 2015 to 5 Feb 2018
Irritable Bowel Syndrome With Constipation · Chronic Idiopathic Constipation
University of Virginian = 30Feb 2015 to Jun 2016
Crohn's · Ulcerative Colitis · Gastrointestinal Bleeding
AbbVien = 12329 Dec 2022 to 2 Sept 2025
Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
AbbVien = 38119 Nov 2019 to 5 Jun 2025
Irritable Bowel Syndrome With Constipation · Functional Constipation
AbbVien = 4381 Oct 2019 to 29 May 2024
Functional Constipation · Irritable Bowel Syndrome With Constipation
Astellas Pharma Incn = 50021 Oct 2014 to 29 Mar 2016
Irritable Bowel Syndrome With Constipation (IBS-C)
Astellas Pharma Incn = 18624 Jun 2016 to 10 Nov 2017
Chronic Constipation
Jiangsu Hansoh Pharmaceutical Co., Ltd.n = 7505 Mar 2021 to est. 31 Aug 2022
Chronic Idiopathic Constipation
Ironwood Pharmaceuticals, Inc.n = 61420 Jun 2018 to 10 Apr 2019
Irritable Bowel Syndrome Characterized by Constipation
Forest Laboratoriesn = 1,55931 Oct 2008 to 31 Jan 2012
Chronic Constipation · Irritable Bowel Syndrome With Constipation
Ironwood Pharmaceuticals, Inc.n = 1,743Sept 2008 to Mar 2012
Irritable Bowel Syndrome With Constipation · Chronic Constipation
Ironwood Pharmaceuticals, Inc.n = 1,223Oct 2014 to Aug 2015
Chronic Idiopathic Constipation
AstraZenecan = 1,722Jul 2013 to May 2015
Irritable Bowel Syndrome With Constipation (IBS-C)
Forest Laboratoriesn = 487Aug 2012 to Aug 2013
Chronic Constipation · Constipation
Ironwood Pharmaceuticals, Inc.n = 805Jul 2009 to Sept 2010
Irritable Bowel Syndrome With Constipation
Ironwood Pharmaceuticals, Inc.n = 643Aug 2008 to Oct 2009
Chronic Constipation
Forest Laboratoriesn = 633Sept 2008 to Aug 2009
Chronic Constipation
Forest Laboratoriesn = 803Jul 2009 to Aug 2010
Irritable Bowel Syndrome Characterized by Constipation
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson Universityn = 15030 Oct 2019 to est. Jan 2027
Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8 · Stage I Colorectal Cancer AJCC v8 · Stage II Colorectal Cancer AJCC v8 · Stage IIA Colorectal Cancer AJCC v8 · Stage IIB Colorectal Cancer AJCC v8 · Stage IIC Colorectal Cancer AJCC v8 · Stage III Colorectal Cancer AJCC v8 · Stage IIIA Colorectal Cancer AJCC v8 · Stage IIIB Colorectal Cancer AJCC v8 · Stage IIIC Colorectal Cancer AJCC v8
8 more mention it but do not test it. They are not trials of Linaclotide: they only measure it (a blood level or an eligibility term) or name it in their text.
Studies on this peptide. Some have results. The others have none yet.
250 studies match. Retracted studies are left out.
Showing 25 of 250 studiesquery qry_4230b28d400c431cf667dbb1
66 studies in all, 19 on this page
Randomized controlled trial · 2012
Chey et al. 2012The American journal of gastroenterologyn = 804cited by 357
PMID 22986437DOI 10.1038/ajg.2012.254PUB-22986437
Randomized controlled trial · 2012
Rao et al. 2012The American journal of gastroenterologyn = 800cited by 314
PMID 22986440PMC3504311DOI 10.1038/ajg.2012.255PUB-22986440
Randomized controlled trial · 2011
Lembo et al. 2011The New England journal of medicinen = 1,276cited by 272
PMID 21830967DOI 10.1056/nejmoa1010863PUB-21830967
Randomized controlled trial · 2013
Castro et al. 2013Gastroenterologyn = 805cited by 236
PMID 23958540DOI 10.1053/j.gastro.2013.08.017PUB-23958540
Randomized controlled trial · 2007
Andresen et al. 2007Gastroenterologyn = 36cited by 178
PMID 17854590DOI 10.1053/j.gastro.2007.06.067PUB-17854590
Animal study (in vivo) · rat · 2010
Busby et al. 2010European journal of pharmacologycited by 172
PMID 20863829DOI 10.1016/j.ejphar.2010.09.019PUB-20863829
Randomized controlled trial · 2010
Johnston et al. 2010Gastroenterologyn = 420cited by 169
PMID 20801122DOI 10.1053/j.gastro.2010.08.041PUB-20801122
Randomized controlled trial · 2010
Lembo et al. 2010Gastroenterologyn = 310cited by 165
PMID 20045700DOI 10.1053/j.gastro.2009.12.050PUB-20045700
Animal study (in vivo) · mouse · 2010
Bryant et al. 2010Life sciencescited by 148
PMID 20307554DOI 10.1016/j.lfs.2010.03.015PUB-20307554
Animal study (in vivo) · mouse and rat · 2010
Eutamene et al. 2010Neurogastroenterology and motilitycited by 147
PMID 19706070DOI 10.1111/j.1365-2982.2009.01385.xPUB-19706070
Non-randomized trial · 2013
Busby et al. 2013The Journal of pharmacology and experimental therapeuticscited by 113
PMID 23090647DOI 10.1124/jpet.112.199430PUB-23090647
Randomized controlled trial · 2013
Quigley et al. 2013Alimentary pharmacology & therapeuticsn = 805cited by 97
PMID 23116208DOI 10.1111/apt.12123PUB-23116208
Randomized controlled trial · 2009
Johnston et al. 2009The American journal of gastroenterologyn = 42cited by 83
PMID 19098860DOI 10.1038/ajg.2008.59PUB-19098860
Animal study (in vivo) · mouse · 2020
Nanto-Hara et al. 2020Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Associationcited by 73
PMID 31411705DOI 10.1093/ndt/gfz126PUB-31411705
Animal study (in vivo) · mouse · 2018
Grundy et al. 2018JCI insightcited by 68
PMID 30282832PMC6237488DOI 10.1172/jci.insight.121841PUB-30282832
Randomized controlled trial · 2015
Lacy et al. 2015PloS onecited by 64
PMID 26222318PMC4519259DOI 10.1371/journal.pone.0134349PUB-26222318
Randomized controlled trial · 2018
Schoenfeld et al. 2018The American journal of gastroenterologycited by 60
PMID 29091082PMC5770595DOI 10.1038/ajg.2017.230PUB-29091082
Randomized controlled trial · 2014
Rao et al. 2014Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Associationcited by 51
PMID 24075889DOI 10.1016/j.cgh.2013.09.022PUB-24075889
Animal study (in vivo) · rat · 2017
Ahsan et al. 2017Physiological reportscited by 47
PMID 28592587PMC5471438DOI 10.14814/phy2.13299PUB-28592587
178 studies in all, 6 on this page
PubMed tag: none · 2019
Moayyedi et al. 2019Journal of the Canadian Association of Gastroenterologycited by 140
PMID 31294724PMC6507291DOI 10.1093/jcag/gwy071PUB-31294724
PubMed tag: Practice Guideline · 2023
Chang et al. 2023Gastroenterologycited by 124
PMID 37211380PMC10542656DOI 10.1053/j.gastro.2023.03.214PUB-37211380
PubMed tag: Practice Guideline · 2022
Chang et al. 2022Gastroenterologycited by 113
PMID 35738724DOI 10.1053/j.gastro.2022.04.016PUB-35738724
PubMed tag: none · 2021
Laps et al. 2021Nature communicationscited by 65
PMID 33558523PMC7870662DOI 10.1038/s41467-021-21209-0PUB-33558523
PubMed tag: none · 2016
Lin et al. 2016Cancer researchcited by 51
PMID 26773096PMC4717834DOI 10.1158/0008-5472.can-15-1467-tPUB-26773096
PubMed tag: Editorial · 2013
Corsetti et al. 2013Neurogastroenterology and motilitycited by 48
PMID 23672677DOI 10.1111/nmo.12151PUB-23672677
Page 1 of 2
Maeda N · The American journal of gastroenterology · 2025
Randomized controlled trial · 5 results
Lembo AJ · The New England journal of medicine · 2011
Randomized controlled trial · 9 results
Yang Y · Journal of gastroenterology and hepatology · 2018
Randomized controlled trial · 5 results
Quigley EM · Alimentary pharmacology & therapeutics · 2013
Randomized controlled trial · 8 results
Chey WD · The American journal of gastroenterology · 2012
Randomized controlled trial · 8 results
Rao S · The American journal of gastroenterology · 2012
Randomized controlled trial · 9 results
Chen H · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026
Randomized controlled trial · 6 results
Peng LH · Journal of digestive diseases · 2022
Randomized controlled trial · 5 results
Chang L · The American journal of gastroenterology · 2021
Randomized controlled trial · 4 results
Fukudo S · Neurogastroenterology and motility · 2018
Randomized controlled trial · 7 results
Di Lorenzo C · The lancet. Gastroenterology & hepatology · 2024
Randomized controlled trial · 8 results
Lembo AJ · Gastroenterology · 2010
Randomized controlled trial · 6 results
Brenner DM · Pain · 2020
Randomized controlled trial · 10 results
Fukudo S · Neurogastroenterology and motility · 2019
Randomized controlled trial · 4 results
Cheng L · Journal of gastroenterology and hepatology · 2025
Randomized controlled trial · 2 results
Person H · Journal of pediatric gastroenterology and nutrition · 2026
Randomized controlled trial · 4 results
Rao SSC · Alimentary pharmacology & therapeutics · 2020
Randomized controlled trial · 15 results
Lacy BE · PloS one · 2015
Randomized controlled trial · 9 results
Schoenfeld P · The American journal of gastroenterology · 2018
Randomized controlled trial · 10 results
Zhang M · European journal of gastroenterology & hepatology · 2021
Randomized controlled trial · 3 results
Fukudo S · Neurogastroenterology and motility · 2018
Randomized controlled trial · 8 results
Wang L · Clinical and translational gastroenterology · 2024
Randomized controlled trial · 3 results
Fukudo S · Neurogastroenterology and motility · 2018
Randomized controlled trial · 6 results
Liu WQ · International journal of colorectal disease · 2024
Randomized controlled trial · 5 results
Di Lorenzo C · Journal of pediatric gastroenterology and nutrition · 2024
Randomized controlled trial · 4 results
Yang J · JGH open : an open access journal of gastroenterology and hepatology · 2023
Randomized controlled trial · 7 results
Johnston JM · The American journal of gastroenterology · 2009
Randomized controlled trial · 7 results
Chang L · Neurogastroenterology and motility · 2026
Randomized controlled trial · 15 results
Buono JL · American health & drug benefits · 2014
Randomized controlled trial · 11 results
Castro J · Gastroenterology · 2013
Randomized controlled trial · 7 results
Johnston JM · Gastroenterology · 2010
Randomized controlled trial · 7 results
Andresen V · Gastroenterology · 2007
Randomized controlled trial · 10 results
Lambiase C · Neurogastroenterology and motility · 2026
Randomized controlled trial · 4 results
Rao SS · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2014
Randomized controlled trial · 4 results
Chey WD · The American journal of gastroenterology · 2021
Randomized controlled trial · 13 results
Nee JW · Expert review of gastroenterology & hepatology · 2019
Randomized controlled trial · 9 results
Song J · Surgical laparoscopy, endoscopy & percutaneous techniques · 2024
Randomized controlled trial · 2 results
Di Lorenzo C · Journal of pediatric gastroenterology and nutrition · 2024
Randomized controlled trial · 5 results
Liu L · Frontiers in medicine · 2026
Randomized controlled trial · 1 result
Lembo A · Alimentary pharmacology & therapeutics · 2023
Randomized controlled trial · 6 results
Sun W · Scandinavian journal of gastroenterology · 2026
Randomized controlled trial · 1 result
Di Lorenzo C · Journal of pediatric gastroenterology and nutrition · 2024
Non-randomized trial · 2 results
Serrano-Falcón B · Therapeutic advances in gastroenterology · 2019
Non-randomized trial · 11 results
Lacy BE · Neurogastroenterology and motility · 2014
Non-randomized trial · 6 results
Brenner DM · The American journal of gastroenterology · 2023
Non-randomized trial · 5 results
Busby RW · The Journal of pharmacology and experimental therapeutics · 2013
Non-randomized trial · 7 results
Chang L · Alimentary pharmacology & therapeutics · 2014
Observational study · 2 results
Busby RW · European journal of pharmacology · 2010
Animal study (in vivo) · rat · 8 results
Bryant AP · Life sciences · 2010
Animal study (in vivo) · mouse · 9 results
Eutamene H · Neurogastroenterology and motility · 2010
Animal study (in vivo) · mouse and rat · 7 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA |
| 27 Oct 2026 | dailymed.nlm.nih.gov (opens in a new tab) |
| EU | EMA |
| 27 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Not listed as banned by WADA The substance is not named in the 2026 list. | 2026 List | wada-ama.org (opens in a new tab) |
57 safety results for Linaclotide.
In colonoscopy outpatients, adverse events were similar with linaclotide and senna on identical PEG-Asc background.
Randomized controlled trialn = 1,464
In chronic constipation patients, adverse event incidence was similar across linaclotide and placebo groups, except for diarrhea.
Randomized controlled trialn = 1,276
In IBS-C patients, diarrhea occurred in 9.4% with linaclotide versus 1.2% with placebo.
Randomized controlled trialn = 839
In IBS-C patients, adverse event incidence was similar with linaclotide and placebo, except for diarrhea.
Randomized controlled trialn = 804
In IBS-C patients, diarrhea caused discontinuation in 5.7% with linaclotide versus 0.3% with placebo.
Randomized controlled trialn = 800
In Chinese IBS-C patients, diarrhea occurred in 8.3% with linaclotide versus 1.2% with placebo.
Randomized controlled trialn = 659
In IBS-C patients, diarrhea occurred in 4.6% with linaclotide versus 1.6% with placebo.
Randomized controlled trialn = 614
In IBS-C patients, adverse event incidence was similar with linaclotide and placebo, except for diarrhea.
Randomized controlled trialn = 420
The top 24 of 57 results.
The doses that these studies used. They are not recommendations.
0.5 mgHuman
290 μg once dailyHuman
290 μg once dailyHuman
290 μg once dailyHuman
290 μg once dailyHuman
290 μg/dHuman
6 of 79 shown
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https:// pepbank.io/ v1/ briefs/ linaclotideEvidence summary for Linaclotide: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 8 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Bowel FunctionGastrointestinal | Human: 85 results from 20 studies: 50 increase, 11 decrease, 3 no significant change, 2 mixed, 19 not reported. Strongest design: Randomized controlled trial | Animal: 6 results from 1 study: 2 increase, 1 decrease, 3 no significant change. Strongest design: Animal study (in vivo) | No results | No results | 91 |
| Gastrointestinal adverse eventsGastrointestinal | Human: 36 results from 21 studies: 14 increase, 2 no significant change, 20 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 36 |
| Gastrointestinal functionGastrointestinal | Human: 35 results from 6 studies: 24 increase, 11 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 35 |
| Bowel PreparationGastrointestinal | Human: 23 results from 9 studies: 13 increase, 1 decrease, 6 no significant change, 3 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 23 |
| PainReproductive and sexual health | Human: 21 results from 9 studies: 9 increase, 9 decrease, 2 no significant change, 1 mixed. Strongest design: Randomized controlled trial | Animal: 20 results from 6 studies: 3 increase, 11 decrease, 6 no significant change. Strongest design: Animal study (in vivo) | Lab: 2 results from 1 study: 1 decrease, 1 no significant change. Strongest design: In vitro (cells) | No results | 43 |
| Gastrointestinal protectionGastrointestinal | Human: 21 results from 5 studies: 13 increase, 3 decrease, 2 no significant change, 3 not reported. Strongest design: Randomized controlled trial | Animal: 8 results from 3 studies: 4 increase, 2 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo) | Lab: 7 results from 2 studies: 2 increase, 1 decrease, 4 no significant change. Strongest design: Ex vivo tissue | No results | 36 |
| Adverse eventsWhole body | Human: 20 results from 15 studies: 3 increase, 4 decrease, 13 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 20 |
| Exercise and physical functionWhole body | Human: 10 results from 1 study: 10 decrease. Strongest design: Randomized controlled trial | No results | No results | No results | 10 |
| IBS Symptom ReliefGastrointestinal | Human: 8 results from 3 studies: 5 increase, 1 decrease, 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 8 |
| Receptor activity and mechanismNervous system and cognition | Human: 6 results from 1 study: 2 increase, 4 no significant change. Strongest design: Randomized controlled trial | Animal: 10 results from 5 studies: 6 increase, 2 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo) | Lab: 14 results from 7 studies: 10 increase, 1 decrease, 3 not reported. Strongest design: Ex vivo tissue | No results | 30 |
| Gastrointestinal SymptomsGastrointestinal | Human: 5 results from 2 studies: 1 increase, 2 decrease, 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 5 |
| Colonic MotilityGastrointestinal | Human: 4 results from 1 study: 2 increase, 2 no significant change. Strongest design: Randomized controlled trial | No results | No results | No results | 4 |
12 outcome groups shown of 33 · 389 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
25 registered trials loaded of 52, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status. The counts cover only the loaded trials.